ALGS (Aligos Therapeutics) Total Assets: $64.56 Mil (As of Mar. 2026)


ALGS Aligos Therapeutics Inc ALGS
37 GF Score
Price $6.63
GF Value $2.78
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Aligos Therapeutics Total Assets?

Aligos Therapeutics ALGS -2.22% 37 Total Assets is $64.56 Mil as of Mar. 2026. GuruFocus rates ALGS with a GF Score™ of 37/100 and a GF Value™ of $2.78 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Aligos Therapeutics's Total Assets for the quarter that ended in Mar. 2026 was $64.56 Mil.

During the past 12 months, Aligos Therapeutics's average Total Assets Growth Rate was -24.80% per year. During the past 3 years, the average Total Assets Growth Rate was -20.00% per year. During the past 5 years, the average Total Assets Growth Rate was -19.30% per year.

During the past 8 years, Aligos Therapeutics's highest 3-Year average Total Assets Growth Rate was 38.30%. The lowest was -33.50%. And the median was -10.20%.

Total Assets is connected with ROA %. Aligos Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 was -120.40%. Total Assets is also linked to Revenue through Asset Turnover. Aligos Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 was 0.04.

Aligos Therapeutics  (NAS:ALGS) Total Assets Explanation

Total Assets is connected with ROA %.

Aligos Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-92.16/( (88.533+64.558)/ 2 )
=-92.16/76.5455
=-120.40 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Aligos Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=2.83/( (88.533+64.558)/ 2 )
=2.83/76.5455
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Aligos Therapeutics Total Assets Related Terms

Aligos Therapeutics Total Assets Historical Data

* Premium members only.

The historical data trend for Aligos Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aligos Therapeutics Total Assets Chart

Aligos Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial 235.37 146.69 151.53 70.09 88.53

Aligos Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 150.70 134.71 109.76 88.53 64.56
ALGS
37GF Score
Aligos Therapeutics Inc ALGS
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aligos Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Aligos Therapeutics's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=53.545+34.988
=88.53

Aligos Therapeutics's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=31.789+32.769
=64.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $64.56 Mil mean?
Aligos Therapeutics (ALGS) has a Total Assets of $64.56 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Aligos Therapeutics and its competitors.
Is Aligos Therapeutics' Total Assets too high?
Aligos Therapeutics' current Total Assets is $64.56 Mil. Overall, Aligos Therapeutics has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aligos Therapeutics' Total Assets compare to SNTI and NTRB?
Aligos Therapeutics' Total Assets of $64.56 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Aligos Therapeutics and its competitors. Aligos Therapeutics's current Total Assets is $64.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aligos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aligos Therapeutics (ALGS) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.78, compared to a current price of $6.63 — trading 138.5% above its estimated fair value. The current Total Assets is $64.56 Mil. Aligos Therapeutics' overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Aligos Therapeutics (ALGS), the current Total Assets is $64.56 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aligos Therapeutics (ALGS) Overvalued in 2026?

Based on GuruFocus' analysis, Aligos Therapeutics stock appears to be overvalued. The current stock price of $6.63 is trading 138.5% above its estimated GF Value™ of $2.78. GuruFocus considers Aligos Therapeutics to be Significantly Overvalued.

Key valuation signals for ALGS:

  • Total Assets: $64.56 Mil
  • GF Value™: $2.78 vs. price of $6.63 (138.5% above fair value)
  • GF Score™: 37/100 with 4 warning signs

No single metric tells the full story. See the ALGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aligos Therapeutics Business Description

Other Exchanges 5WK0:Germany
Address One Corporate Drive, 2nd Floor, South San Francisco, CA, USA, 94080
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
37GF Score

Get the complete analysis for ALGS

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.63
Price
$2.78
GF Value